- Home
- TURN vs UNCY Comparison
TURN vs UNCY Comparison
Compare TURN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- UNCY
- Stock Information
- Founded
- TURN 1981
- UNCY 2016
- Country
- TURN United States
- UNCY United States
- Employees
- TURN N/A
- UNCY N/A
- Industry
- TURN Finance/Investors Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- UNCY Health Care
- Exchange
- TURN Nasdaq
- UNCY Nasdaq
- Market Cap
- TURN 35.7M
- UNCY 31.9M
- IPO Year
- TURN N/A
- UNCY 2021
- Fundamental
- Price
- TURN $3.65
- UNCY $0.66
- Analyst Decision
- TURN
- UNCY Strong Buy
- Analyst Count
- TURN 0
- UNCY 4
- Target Price
- TURN N/A
- UNCY $5.50
- AVG Volume (30 Days)
- TURN 37.2K
- UNCY 1.5M
- Earning Date
- TURN 08-19-2024
- UNCY 11-13-2024
- Dividend Yield
- TURN N/A
- UNCY N/A
- EPS Growth
- TURN N/A
- UNCY N/A
- EPS
- TURN N/A
- UNCY N/A
- Revenue
- TURN $129,297.00
- UNCY N/A
- Revenue This Year
- TURN N/A
- UNCY N/A
- Revenue Next Year
- TURN N/A
- UNCY N/A
- P/E Ratio
- TURN N/A
- UNCY N/A
- Revenue Growth
- TURN 6.32
- UNCY N/A
- 52 Week Low
- TURN $3.12
- UNCY $0.20
- 52 Week High
- TURN $4.47
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- TURN 55.40
- UNCY 52.04
- Support Level
- TURN $3.61
- UNCY $0.62
- Resistance Level
- TURN $3.75
- UNCY $0.87
- Average True Range (ATR)
- TURN 0.11
- UNCY 0.08
- MACD
- TURN -0.01
- UNCY -0.01
- Stochastic Oscillator
- TURN 42.86
- UNCY 15.45
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.